Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer
Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Aug 24, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PREDAtOOR clinical trial is a study designed to improve treatment choices for women with advanced ovarian cancer, specifically those in Stage III and IV. Researchers want to use a special technology called Camera Vision (CV) during a procedure known as diagnostic laparoscopy. This procedure helps doctors see inside the abdomen and gather information about the cancer. By analyzing the patterns of the cancer’s spread, the study aims to predict how well patients might respond to a type of surgery called cytoreduction, which helps remove as much of the tumor as possible.
To participate in this trial, women need to be between the ages of 65 and 74 and diagnosed with advanced ovarian cancer, ready for surgery after receiving some initial treatment. Eligible participants will be those treated at specific hospitals in Italy and Canada. Unfortunately, those with early-stage cancer or certain rare types of ovarian tumors will not be included. While the trial is not yet recruiting participants, it is an important step toward finding better ways to tailor treatments for patients, helping doctors make more informed decisions.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients treated at Fondazione Policlinico Gemelli Hospital, Rome Italy, Trillium -Credit Valley Hospital, Mississauga, Ontario and Princess Margaret Cancer Centre, Toronto, Canada
- • Patients fit for cytoreductive surgery
- • Patients with a primary diagnosis of suspect Stage III-IV ovarian cancer
- • Patients selected for interval cytoreductive surgery after NACT
- Exclusion Criteria:
- • Patients with pre-operative Stage I-II disease confined to the pelvis
- • Patients unfit for surgery
- • Lack of information about patients' surgical outcomes and clinicopathological characteristics
- • LGSOC, Clear cell and mucinous, non-epithelial histologic subtypes (if available)
About Fondazione Policlinico Universitario Agostino Gemelli Irccs
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is a leading research and healthcare institution based in Rome, Italy, renowned for its commitment to advancing medical science and improving patient care. As a prominent academic medical center affiliated with the Catholic University of the Sacred Heart, it integrates clinical practice, education, and research, fostering innovation in various fields of medicine. The foundation conducts a wide range of clinical trials aimed at developing new therapies and enhancing treatment protocols, with a focus on translational research that bridges the gap between laboratory discoveries and patient care. Its multidisciplinary approach and dedication to high ethical standards position it as a key player in the landscape of clinical research and healthcare improvement in Italy and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roma, , Italy
Patients applied
Trial Officials
Anna Fagotti, Prof
Principal Investigator
Fondazione Policlinico Universitario A. Gemelli, IRCCS
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported